11/12/2024

Liraglutide Injection

Products Affected - Description

- Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00169-4060-12
- Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00169-4060-13

Reason for the Shortage

- Novo Nordisk has Victoza on shortage due to manufacturing delays.
- Novo Nordisk has Saxenda available.
- Teva launched the authorized generic of liraglutide in late-June 2024.

Available Products

- Saxenda subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 5 count, NDC 00169-2800-15
- Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00480-3667-20
- Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00480-3667-22

Estimated Resupply Dates

- Novo Nordisk has Victoza 6 mg/mL 3 mL pens in 2 and 3 count presentations on back order and the company estimates a release date in late-December 2024.

Updated

Updated November 12, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 20, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.